Bidding war for Beijing-based Sinovac Biotech continues

10 August 2017

Shares in Beijing-based Sinovac Biotech (Nasdaq: SVA) are up 1% after morning trading in New York, following the news that Sinobioway Consortium has upped its offer to buy the firm, from $7 to $8 per share.

Sinobioway, a group of Chinese investment firms focused on healthcare, submitted verification of the financial basis for the offer two weeks ago, upon request.

The consortium is engaged in a long-running bidding war with another group of investors, led by Sinovac chief executive Weidong Yin and Indian venture capitalists SAIF Partners.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK